CONFERECE PROGRAM

Conference Cochairs
Douglas A. Levine, NYU Langone Health, New York, NY
Blake Gilks, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada
Victoria L. Bae-Jump, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC

*Five minute (5 slide max) audio poster short talks in a single poster session will be released at the start of the conference and available on-demand throughout*

**Presentations will be prerecorded. Presentation times are as follows: Keynote (30 minutes and 10 minutes for live Q&A); other invited presentations (20 minutes and 10 minutes for live Q&A), short talks selected from proffered abstracts, if applicable (10 minutes and 5 minutes for live Q&A)**

MONDAY, NOVEMBER 9, 2020

10:00 AM-11:30 AM  WELCOME AND EDUCATION SESSION
Introduction by Douglas A. Levine, NYU Langone Health, New York, NY, C. Blake Gilks, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada, Victoria L. Bae-Jump, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC

10:00 AM-10:30 AM  Management of newly diagnosed endometrial cancers and molecular classification
Douglas A. Levine

10:30 AM-11:00 AM  Histopathology classification of endometrial cancers and surrogate markers of genomic subtypes
C. Blake Gilks

11:00 AM-11:30 AM  Navigating the complex world of adjuvant treatments and clinical trials
Victoria L. Bae-Jump

11:30 AM-11:45 AM  BREAK

11:45 AM-1:30 PM  PLENARY SESSION 1: Targeted Therapeutics
Session Chair: Victoria L. Bae-Jump, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC

11:45 AM-12:15 PM  Challenges for future adjuvant studies and the role of immunotherapy in endometrial cancer  
Remi A. Nout, Leiden University Medical Center, Leiden, Netherlands

12:15 PM-12:45 PM  DNA damaging agents in endometrial cancer  
Shannon Neville Westin, The University of Texas MD Anderson Cancer Center, Houston, TX

12:45 PM-1:15 PM  Endocrine therapy and ER/PR combinations  
Helen J. MacKay, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

1:15 PM-1:30 PM  Preclinical development of SHetA2 for endometrial cancer therapy*  
Doris M. Benbrook, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK

1:30 PM-1:45 PM  BREAK

1:45 PM-3:45 PM  PLENARY SESSION 2: Functional Genomics and Proteomics  
Session Chair: Russell R. Broaddus, University of North Carolina School of Medicine, Chapel Hill, NC

1:45 PM-2:15 PM  The mutational landscape of normal human endometrial epithelium  
Luiza Moore, Wellcome Trust Sanger Institute, Cambridge, England

2:15 PM-2:45 PM  Mismatch repair deficiency and survival in stage I endometrial cancer  
Russell R. Broaddus

2:45 PM-3:15 PM  Proteogenomic characterization of endometrial carcinoma  
David Fenyo, NYU Langone Health, New York, NY

3:15 PM-3:30 PM  Global proteomic profiling of endometrial carcinomas identify prognostic markers*  
Dawn R. Cochrane, BC Cancer Research Centre, Vancouver, BC, Canada

3:30 PM-3:45 PM  Multi-tissue transcriptome-wide association study identifies genetic mechanisms underlying endometrial cancer susceptibility*  
Tracy M. O’Mara, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
3:45 PM-4:00 PM  BREAK

4:00 PM-5:00 PM  PLENARY SESSION 3: Immunotherapy
  Session Chair: Dmitriy Zamarin, Memorial Sloan Kettering Cancer Center, New York, NY

4:00 PM-4:30 PM  Immunology of endometrial cancers: Tumor genetics, immune recognition, and immunotherapy response
  Dmitriy Zamarin

4:30 PM-5:00 PM  Coordinated T and B cell responses exert immune pressure against malignant progression
  Jose R. Conejo-Garcia, Moffitt Cancer Center, Tampa, FL

TUESDAY, NOVEMBER 10, 2020

10:00 AM-10:45 AM  KEYNOTE LECTURE
  Introduction by Douglas A. Levine, NYU Langone Health, New York, NY
  Recent progress with PTEN
  Ramon Parsons, Icahn School of Medicine at Mount Sinai, New York, NY

10:45 AM-11:00 AM  BREAK

11:00 AM-12:30 PM  PLENARY SESSION 4: DNA Repair and Replication
  Session Chair: Tjalling Bosse, Leiden University Medical Center, Leiden, Netherlands

11:00 AM-11:30 AM  Endometrial carcinomas with a mutation in DNA polymerase epsilon: A pathologist view
  Tjalling Bosse
11:30 AM-12:00 PM  
**POLE mutations in endometrial cancer: Consequences and mechanisms**  
Polina V. Shcherbakova, University of Nebraska Medical Center, Omaha, NE

12:00 PM-12:15 PM  
**Multi-dimensional biomarker analyses identify pembrolizumab responders in advanced stage, high grade endometrial cancer**  
Katherine C. Fuh, Washington University School of Medicine, St. Louis, MO

12:15 PM-12:30 PM  
**CD73 sequestering mutant β-catenin at the membrane explains recurrence in CTNNB1 mutant endometrial cancer**  
Jessica L. Bowser, University of North Carolina School of Medicine, Chapel Hill, NC

12:30 PM-12:45 PM  
**BREAK**

12:45 PM-2:45 PM  
**PLENARY SESSION 5: Molecular Stratification**  
*Session Chair: Jessica N. McAlpine, University of British Columbia, Vancouver, BC, Canada*

12:45 PM-1:15 PM  
**Molecular stratification: Beyond TCGA**  
David Church, Wellcome Centre for Human Genetics, University of Oxford, Oxford, England

1:15 PM-1:45 PM  
**Molecular stratification: p53abnormal endometrial carcinoma; the low-hanging fruit**  
Naveena Singh, Barts Health NHS Trust, London, England

1:45 PM-2:15 PM  
**Molecular classification and stratification: Diving deeper**  
Jessica N. McAlpine

2:15 PM-2:30 PM  
**Correlation of immunohistochemistry with TP53 sequence and clinical outcomes in GOG-086**  
Kimberly K. Leslie, University of Iowa, Iowa City, IA

2:30 PM-2:45 PM  
**Genomic characterisation of endometrial cancer patient-derived xenografts reveals intratumour heterogeneity**  
Olga Kondrashova, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia

2:45 PM-3:00 PM  
**BREAK**
### PLENARY SESSION 6: Novel Model Systems

**Session Chair:** Victoria L. Bae-Jump, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 PM-3:30 PM</td>
<td><strong>Breaking the obesity-endometrial cancer link: Lessons from preclinical studies</strong></td>
<td>Stephen D. Hursting</td>
<td>University of North Carolina Chapel Hill, Chapel Hill, NC</td>
</tr>
<tr>
<td>3:30 PM-4:00 PM</td>
<td><strong>Organoids to model endometrial carcinoma subtypes</strong></td>
<td>David G. Huntsman</td>
<td>British Columbia Cancer Research Center, Vancouver, BC, Canada</td>
</tr>
<tr>
<td>4:00 PM-4:30 PM</td>
<td><strong>Chromatin regulation of the endometrium: What are our models telling us?</strong></td>
<td>Ronald L. Chandler</td>
<td>Michigan State University, Grand Rapids, MI</td>
</tr>
<tr>
<td>4:30 PM-4:45 PM</td>
<td><strong>Identifying mechanisms of immune evasion in microsatellite instable endometrial cancer mouse models</strong></td>
<td>Brenda Melendez</td>
<td>The University of Texas MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>4:45 PM-5:00 PM</td>
<td><strong>Characterization of patient-derived xenograft models of endometrial cancer</strong></td>
<td>Kristina W. Thiel</td>
<td>University of Iowa, Iowa City, IA</td>
</tr>
</tbody>
</table>

*Short talk from proffered abstract*